CA Patent

CA3073998A1 — Improved treatment of atopic dermatitis with tradipitant

Assigned to Vanda Pharmaceuticals Inc · Expires 2019-03-21 · 7y expired

What this patent protects

The disclosure relates to improved methods of treatment of atopic dermatitis and symptoms thereof with tradipitant.

USPTO Abstract

The disclosure relates to improved methods of treatment of atopic dermatitis and symptoms thereof with tradipitant.

Drugs covered by this patent

Patent Metadata

Patent number: CA3073998A1
Jurisdiction: CA
Classification: —
Expires: 2019-03-21
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.